Published On: Thu, Mar 17th, 2016

Neos Therapeutics, Inc. (NASDAQ:NEOS) Expected To Report Earnings On Wednesday

Analysts await Neos Therapeutics, Inc. (NASDAQ:NEOS) to report earnings on Mar, 17 for the fiscal quarter ending Dec 2015.

They expect $-0.74 EPS, down 100% or $0.74 from last year’s $n/a per share.

At the moment 4 analysts are watching Neos Therapeutics, Inc. (NASDAQ:NEOS), 2 rate it “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 2 analysts have a mean sales target of 1.45 million. For the quarter ending Jun-16, 2 analysts have a mean sales target of 4.70 million whilst for the year ending Dec-16, 4 analysts have a mean target of 13.68 million.

In terms of earnings per share, 2 analysts have a -0.96 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 2 analysts have a -1.12 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of -3.71 EPS.

The biggest institutional shareholders in Neos Therapeutics, Inc. include Presidio Partners which owns 2 million shares in the company valued at $24.03 million. Kearny Venture Associates, L.L.C. is the second biggest holder with 1 million shares currently valued at 0.00 million whilst Franklin Advisers, Inc. has 1 million shares valued at 17.93 million.

Total shares held by institutions as of the most recent company filings are 6,385,447 with a reported 170,645 bought and 434,682 sold. These holdings make up 40.05% of the company’s outstanding shares.

Currently insiders hold 1,710,529 shares in the business which makes up 10.73% of shares. The biggest holder currently is Jack W Schuler who owns 1,044,578 shares (6.55% of those outstanding), whilst Alan L. Heller holds 369,888 (2.32% of shares outstanding) and Dr. Vipin K. Garg, PhD holds 135,352 (0.85% of shares outstanding).

The stock decreased 6.79% or $0.71 during the last trading session.

Receive News & Ratings Via Email

Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: